@cbronsonmd's hCG on TRT claims need more context

What did @cbronsonmd actually say?

The claim here is fairly specific: 500 IU of hCG every other day is the studied, established dose for men on TRT, and 250 IU every other day might also work. The creator also mentions sourcing hCG from India, framing it as a cost-saving move.

To be precise about the transcript: "500 is the one that was studied" and "can maybe get away with 250." That phrasing matters. He's not pulling numbers from nowhere, but the confidence level implied by "the one that was studied" overstates what the evidence actually shows. There's a range in the literature, not a single consensus dose, and the sourcing comment raises its own regulatory red flags worth addressing separately.

Does the science back this up?

Partially, yes. The 500 IU every-other-day protocol does appear in peer-reviewed literature and has been used clinically for decades. But calling it definitively "the one that was studied" is an oversimplification that papers over a messier evidence base.

Coviello et al. (2005, Journal of Clinical Endocrinology and Metabolism) found that hCG doses as low as 125 IU every other day maintained intratesticular testosterone in men on exogenous testosterone, with 500 IU achieving near-complete preservation. That study is probably the most cited source for this dosing range and does support the creator's numbers. However, Wenker et al. (2015, Journal of Urology) and other fertility-focused studies use different protocols entirely. The honest read is that 500 IU EOD is a reasonable, well-supported option, not the singular gold standard. The 250 IU comment also has some support from Coviello's dose-response data, so that's not fabricated either.

What did they get wrong (or right)?

The dosing range itself is defensible. Give credit where it's due. The bigger problem is the framing and the sourcing comment.

Saying "500 is the one that was studied" implies scientific unanimity that doesn't exist. Coviello 2005 is a small study with 29 participants. It's influential but not a randomized controlled trial with thousands of subjects. Building definitive dosing language on it is a stretch.

The India sourcing comment is a separate and more serious issue. Unregulated pharmaceutical imports carry real risks: variable potency, contamination, and in most jurisdictions, legal exposure. Compounded hCG from a licensed compounding pharmacy and pharmaceutical-grade hCG from a foreign unverified supplier are not the same thing, and presenting informal international sourcing as a casual cost-cutting tip is genuinely irresponsible advice in a public forum. It sidesteps every quality control system that exists for a reason.

• What he got right: the 500 IU EOD figure has legitimate study support
• What he got right: 250 IU is also within studied ranges
• What he got wrong: calling 500 IU definitively "the one that was studied"
• What he got wrong: normalizing unverified foreign pharmaceutical sourcing

What should you actually know?

hCG is used alongside TRT primarily to preserve testicular size, maintain intratesticular testosterone, and support fertility potential in men who want to keep options open. It works by mimicking LH, stimulating the Leydig cells that exogenous testosterone suppresses.

The Coviello 2005 data suggests a dose-response relationship where 125 to 500 IU EOD covers a functional range, with diminishing returns above 500 IU and potential estradiol elevation at higher doses. That estradiol piece matters practically. More hCG is not always better, and some men will aromatize the additional intratesticular testosterone into estrogen at doses toward the higher end.

Anyone considering hCG as part of a TRT protocol should be working with a licensed provider who can monitor LH receptor response, estradiol levels, and sperm parameters if fertility is a goal. Sourcing medications through unverified international suppliers bypasses every safety check that prescription-based care exists to provide. The cost savings are real. The risks are also real.